RU1776408C - Method for treatment of glomerulonephritis cases - Google Patents

Abstract

The invention relates to medicine, in particular to nephrology. The purpose of the invention is to reduce the complications of the treatment of glomerulonephritis. For this, conventional therapy uses delagil in combination with calcium dobesylate.

Description

The invention relates to medicine, namely to nephrology, and can be used for the prevention of acute renal failure, mainly in the acute, subacute and chronic course of glomerulonephritis in the presence of urinary syndrome with a hematuric component.

The purpose of the invention is to improve the clinical effect, to eliminate side effects and the development of acute renal failure; reduction of complications of therapy.

This goal is achieved by the fact that according to the method of treating glomerulonephritis, a combined course of delagil, a preparation of 4-aminocholine and calcium dobesilate, a drug that helps increase the hemostatic activity of platelets, reduces the activity of kinins and hyaluronidase, reduces permeability and fragility of capillaries.

The method is carried out as follows: 1. Delagil is prescribed 0.25 g 2 times a day (morning and evening), 30 minutes after a meal for 10 days, then reduce the dose to 0.25 g 1 time per day , at night, for 4 months daily. 2. Dobesylate-calcium is prescribed 0.25 g 4 times a day, during meals, for 1 month, then the dose of the drug is reduced by 0.25 g every 30 days.

The proposed method is confirmed by specific examples.

Example 1. Patient D., 18 years old, medical history No. 587/88, was treated in a hospital with a diagnosis of acute glomerulonephritis, urinary syndrome, hematuric component. The diagnosis was established on the basis of clinical, laboratory and instrumental examination. The performed therapy (chimes, indomethacin, burden, infusion of herbs) did not alter the urinary syndrome and the patient was discharged with the following tests: general urinalysis: beats. weight. - 1012, protein - 0.099 g / l, acid reaction, leukocytes - 0-1 in n / a. Red blood cells - little changed and alkaline 80-100 in n / a.

Test Amburge: ud. weight - 1020. Red blood cells cover the entire field of vision, counting is impossible.

A course of delagil and dobesylate-calcium was prescribed according to the above scheme. After 1 month of treatment, the analyzes were as follows: general urinalysis: beats. weight - 1025, protein 0.33 g / l, acid reaction, white blood cells

1 VI CN

About 00

-1 -3 in s / sp., Erythrocytes - 45-50 in s / sp., Little changed, in places up to 60. Amburge test: beats. weight - 1025, white blood cells - 1.008 103 l / min, red blood cells - 35.280-10 l / min.

After 2 months of treatment: general urinalysis: beats. weight - 1020, protein - 0.297 g / l, acid reaction, leukocytes - 1-2 p / sp., red blood cells 15-20 in p / sp., leached. Test Amburge: ud. weight - 1020, white blood cells - 1.016 "103 l / min, red blood cells - 5.150 x 103 l / min,

After 3 months of treatment: general urinalysis: beats. weight - 1030, protein - 0.165 g / l, acid reaction, leukocytes - 3-5 p / sp., erythrocytes - 0-2 in p / sp., leached. Test Amburge: ud. weight - 1030, red blood cells - 2.310-U3 l / min, white blood cells - 1.01010 l / min.

After 4 months of treatment: general urinalysis: beats. weight - 1028, protein - 0.033 g / l, acid reaction, leukocytes 1-3 in s / sp., erythrocytes - 0-1-2 in s / sp., little changed. Test Amburge: ud. weight - 1028, red blood cells - 1.004 103 min, white blood cells - 0, l / min.

Example 2. Patient J., 53 years old, after examination in a hospital and establishing a diagnosis: primary chronic glomerulonephritis, urinary syndrome, hematuric component, in the acute phase, was treated on an outpatient basis in the 20th polyclinic of the Kiev region of Odessa. Before treatment according to the above scheme: general urinalysis: beats. weight - 1023. protein - 0.99 g / l, acid reaction, leukocytes - 3-5 p / sp., red blood cells - 45-50 p / sp., leached, hyaline cylinders - 3 in p / sp. Test Amburge: ud. weight. - 1020, white blood cells - 1.083103 l / min, red blood cells-78, 596 103l / min.

One month after treatment: general urinalysis: beats. weight - 1018, protein - 0.66 g / l, acid reaction, leukocytes - 1-2 p / sp., erythrocytes - 30-35 in p / sp., leached. Test Amburge: ud. weight. - 1020, white blood cells

-0.896 103 l / min, red blood cells - 52.487-103 l / min.

2 months after treatment: general urine analysis: beats, weight - 1015, protein - 0.33 g / l, acid reaction, white blood cells - 1-2 in s / sp, erythrocytes -25-30 in s / sp. leached. Amburge test: beats, weight - 1015, white blood cells - 0.639103 l / min, red blood cells - 36.254-103 l / min.

3 months after treatment: general urinalysis: beats. weight 1015, protein 0.33 g / l, acid reaction, leukocytes 0-1 in s / sp, erythrocytes 15-20 in s / sp, leached. Test Amburge: ud. weight - 1018, white blood cells - 0.625-J3 l / min, red blood cells - 17.126-J3 / min,

4 months after treatment; general urine analysis: beats, weight - 1018, protein 0, 099 g / l, acid reaction, leukocytes - 1-2 in n / a, red blood cells - 8-10 in n / a, leached. Test Amburge: ud. weight - 1015, white blood cells - 0.432-10 l / min, red blood cells 6, 128-U3 l / min.

Example 3. Patient B., 52 years old, was treated on an outpatient and inpatient basis with a diagnosis of secondary chronic glomerulonephritis, urinary syndrome, hematuric component, latent course.

The effect of the therapy was not received. The proposed dosage regimen has been prescribed.

Before treatment according to the scheme: general urinalysis: beats. weight 1018, protein 0.165 g / l, acid reaction, leukocytes 8-10 in s / sp., red blood cells 50-60 in s / sp, leached. Test Amburge: ud. weight - 1020, white blood cells 2, 189-103 l / min, red blood cells - 86.752-103 l / min. One month later, c after treatment; beats weight - 1020, protein - 0.099 g / l, acid reaction, leukocytes - 4-6 p / sp., erythrocytes - 45-50 in p / sp., leached. Test Amburge: ud.

weight - 1015, white blood cells - 1.385-10 l / min, red blood cells - 36.278103 l / min.

2 months after treatment: general urinalysis: beats. weight - 1018, protein - 0.066 g / l, leukocytes - 1-2 in s / sp., red blood cells - 25-30 in s / sp., little changed, Amburge test: beats. weight - 1015, white blood cells - 1.008103 l / min, red blood cells - 10.026 103 l / min.

After 3 months of treatment: general analysis

urine: ud. weight - 1015, protein - 0.033 g / l, acid reaction, leukocytes - 0-1 in n / a, red blood cells - 8-10 in n / a, little changed. Test Amburge: ud. weight - 1014, white blood cells - 0.652-J3 l / min, red blood cells 5, 123-J3 l / min.

After 4 months of treatment: general urinalysis: beats. weight - 1018, protein - 0.033 g / l, acid reaction, leukocytes - 0-1 in s / sp., erythrocytes - 4-5 in s / sp., leached. Try

Amburge: ud. weight - 1015, white blood cells - 0.424 10 l / min, red blood cells - 1,036-L3 l / min.

The proposed method has high therapeutic efficacy, has no side effects, is safe and generally available in medical institutions of a therapeutic profile, both in hospitals and clinics. The method is also preventive, with its help it is possible to prevent the development

acute renal failure.

Claims (1)

SUMMARY OF THE INVENTION A method for treating glomerulonephritis comprising administering delagil in combination with an angioprotective agent liable to that. that, with the aim of reducing the protective effect, dobesylate is used to calculate the complications of therapy as ancy.